Clinical trial
Antineoplaston Therapy in Treating Patients With Recurrent or Refractory…
NCT00003512 · Burzynski Research Institute, Other · Withdrawn
Key facts
| NCT number | NCT00003512 |
|---|---|
| Title | Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Waldenstrom's Macroglobulinemia |
| Official title | Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Macroglobulinemia of Waldenstrom |
| Lead sponsor | Burzynski Research Institute, Other |
| Status | Withdrawn |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Waldenstrom Macroglobulinemia |
| Intervention type | Drug |
| Interventions | Antineoplaston therapy (Atengenal + Astugenal) |
| Enrollment | 0 |
| Start date | Feb 18, 1999 |
| Primary completion | Apr 26, 2000 |
| Completion | Apr 26, 2000 |
| First posted | Jan 27, 2003 |
| Last update posted | Feb 5, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: